Switch Therapeutics
Si-ping Han is a highly accomplished professional with a strong background in material science and physics. Currently serving as Co-founder and CEO of NewCo since January 2024, Si-ping is also a Co-founder and Chief Technology Officer at Switch Therapeutics since July 2020. Prior experience includes roles as a Postdoctoral Fellow and Visiting Postdoc at City of Hope from 2010 to July 2020, and a Postdoctoral Scholar at the California Institute of Technology from September 2010 to July 2020. Si-ping earned a PhD in Material Science and a Bachelor’s Degree in Physics from Caltech, where education was completed from 2004 to 2010.
This person is not in any teams
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.